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Article / Clinical Case Report
ABSTRACT
High-grade endometrial carcinomas are aggressive neoplasms of difficult histological classification. Neuroendocrine 
differentiation in endometrial carcinomas is rare. This is the report of an endometrial large cell neuroendocrine 
carcinoma with foci of melanocytic differentiation in a 75-year-old woman with abnormal post-menopausal uterine 
bleeding for 2 years. Two initial biopsies were inconclusive. Histopathological examination of the uterus revealed large 
cell neuroendocrine carcinoma associated with endometrioid carcinoma and foci of melanocytic differentiation, pT3a 
(FIGO IIIA). There were metastases in the rectum serosa and lungs. After 8 months of diagnosis and surgical treatment, 
the patient is on chemotherapy and radiotherapy. We highlight the morphological characteristics and criteria that allow 
the definitive anatomopathological diagnosis, including immunohistochemical markers used to identify the cell types 
present in this unprecedented association. 
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INTRODUCTION
Endometrial carcinoma is the most common 
invasive neoplasm of the female genital tract.1,2 Data 
from the Brazilian National Cancer Institute (INCA) 
estimate an incidence of 6.2 cases of uterine and ovarian 
malignancies per 100,000 women in the southeastern 
region of Brazil in 2018.3 Such tumors may present a 
diagnostic challenge at microscopy, especially when they 
are poorly differentiated neoplasms of high histological 
grade. Neuroendocrine differentiation is uncommon. 
High-grade neuroendocrine carcinomas correspond to 
less than 1% of endometrial neoplasms.4 Endometrial 
neuroendocrine carcinomas are underdiagnosed 
in 89% of cases5; most are of large cell type and 
associated with other histological types, especially 
endometrioid carcinoma.5-7
Melanocytic differentiation in endometrial 
neoplasms is even more uncommon. There are rare 
reports of melanocytic differentiation in carcinosarcoma 
and benign melanocytic lesions in the endometrium.8-11 
We present the rare case of a primary endometrial large 
cell neuroendocrine carcinoma with foci of melanocytic 
differentiation.
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CASE REPORT
A 75-year-old Brazi l ian non-white female 
attended the hospital reporting abdominal pain and 
post-menopausal bleeding for 2 years. Transvaginal 
ultrasonography (TVU) showed the uterus in 
anteversion, with regular contours, 5.7 × 3.5 × 4.8 cm, 
and 52.9 cm3, plus myometrium with homogeneous 
echotexture. The endometrium was 0.32 cm of 
thickness and a bulky endometrial polyp measuring 
3.5 × 2.5 cm with a stalk in the uterine posterior 
wall was observed. Both ovaries had an atrophic 
appearance, 1.8 × 1.2 × 1.2 cm, and 1.4 cm3 (right); and 
1.7 × 0.8 × 1.7 cm, and 1.4 cm3 (left). Cervicovaginal 
cytopathological examination found Gardnerella sp. 
and inflammation; neoplasm was absent. Hysteroscopy 
was recommended for removal of the polyp; however, 
the patient only returned to the hospital for further 
treatment after 14 months. In a new TVU, the 
uterus was 8.0 × 5.5 × 5.2 cm, and 120.4 cm3; the 
endometrium had heterogeneous echogenicity and was 
markedly thickened; and there was a solid projection 
within the uterine cavity, shown with Doppler flow. 
Both adnexae were uremarkable. Cervicovaginal 
cytology showed atypical cells, which was suggestive 
of invasive endometrial adenocarcinoma. The patient 
underwent hysteroscopy to remove the polyp. 
Histopathological examination demonstrated a necrotic 
pleomorphic neoplasm, which was undefined between 
pleomorphic rhabdomyosarcoma, undifferentiated 
carcinoma, and poorly differentiated adenocarcinoma. 
Due to extensive necrosis present in the sample, 
the immunohistochemical study was inconclusive. 
The patient was then hospitalized and underwent 
biopsy curettage. Immunohistochemistry was negative 
for all markers (AE1/AE3, desmin, PAX-8, S-100, 
myogenin). The tumor was labeled as epithelioid 
malignant neoplasm with extensive necrosis. Then, 
extended total hysterectomy (ETH) and adnexectomy 
were performed.
Gross findings (Figure 1) showed a pyriform uterus 
of 168g and 9 × 5 × 5 cm. In the uterine cavity, there 
was a pedunculated polypoid mass that occupied and 
expanded the entire cavity, with infiltration of more 
than 50% of the myometrial thickness in its base. 
The polypoid mass was 7.5 × 3.5 cm, predominantly 
white, soft, and shiny, with interspersed black areas. 
At the cervix, it was red and elastic.
Microscopic analysis showed a heterogeneous 
neoplasm, with glandular areas, solid areas that 
corresponded to more than 10% of the neoplasm, 
large bizarre atypical cells, and extensive regions of 
necrosis.
In the solid areas, the cells presented an occasional 
trabecular arrangement or nesting (Figure 2A), large 
nuclei, finely granular chromatin and occasional 
nucleoli, scarce cytoplasm interposed with cells that had 
bulky and bizarre nuclei (Figure 2B), and eosinophilic 
cytoplasm. Extensive vascular neoplastic infiltration 
was observed. The cells were positive for cytokeratin 
(AE1/AE3), synaptophysin (Figure 2C), chromogranin 
A and p16, and—weakly—for CD56. The mitotic 
index was higher than 10 mitoses/high power field, 
and the cell proliferation index, calculated by Ki-67 
immunostaining, was 50%. In neoplastic glands, the 
cells were cohesive with vesicular and pleomorphic 
nuclei and eosinophilic cytoplasm, allowing the 
Figure 1. Gross features: a pedunculated polypoid 
endometrial mass with interspersed black and 
hemorrhagic areas.
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diagnosis of endometrioid carcinoma of high nuclear 
grade. Occasionally, and in correspondence to the 
macroscopic black areas, there were cells with clear 
cytoplasm and granular brown pigment (Figure 2D).
Immunohistochemistry showed the expression of 
Melan-A in a greater extent than that occupied by cells 
with cytoplasmic pigment (Figure 3).
The carcinoma involved the anterior and posterior 
walls of the uterine body and isthmus to the subserosa. 
Extensive neoplastic infiltration was observed in the 
right mesosalpinx. The right ovary and left adnexa 
were free of neoplasia. There were metastases of 
undifferentiated large cell carcinoma in the rectum 
serosa, and pelvic lymph nodes were not resected. 
Staging was pT3aNxM1, FIGO IIIA.
Ches t  x - ray  o rde red  a f te r  ETH showed 
pulmonary metastasis. The patient was referred to 
radiotherapy for endometrial neoplasia with a dose 
of 4,500 cGy, 25 doses, and chemotherapy (cisplatin 
Figure 3. Photomicrograph of the tumor showing 
expression of melan-A in part of the neoplastic cells (40x).
120mg + cyclophosphamide 830mg), six cycles of 
28 days each. During treatment, she reported weight 
loss, 2.7 kg, hyporexia, and 10/10 intense burning 
vaginal pain. She was discharged from radiotherapy 
Figure 2. Photomicrograph of the tumor showing in A – nesting pattern (HE, 20x); B – Large cells with bulky 
and bizarre nuclei (HE, 40x); C – Neoplastic cells show strong cytoplasmic expression of synaptophysin (40x); 
D – Melanocytic differentiation: cells with granular brown pigment (HE, 40x).
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and referred for complementary treatment with 
brachytherapy. Currently, 8 months after diagnosis, 
the patient is stable, is followed up by oncology, and 
is waiting for brachytherapy.
DISCUSSION
High-grade endometrial malignancies may be 
extremely heterogeneous neoplasms, which are 
histologically difficult to classify.12 The microscopic 
features of large cell neuroendocrine carcinomas at 
hematoxylin & eosin (H&E) staining may mimic several 
other malignant neoplasms, such as poorly differentiated 
adenocarcinoma, undifferentiated sarcoma, malignant 
mixed Müllerian tumor, undifferentiated carcinoma, 
primitive neuroectodermal tumor, and atypical 
carcinoid tumors.5,13,14 There are various associations 
of large cell neuroendocrine carcinomas with other 
endometrial malignancies: endometrioid carcinoma, 
serous carcinoma, and undifferentiated sarcomatoid 
carcinoma.4,15,16 In the fourth edition of the WHO 
Classification of Tumors of Female Reproductive 
Organs, neuroendocrine carcinomas of large cells are 
defined as neoplasms that show a “neuroendocrine 
growth pattern in at least part of the tumor, with 
expression of one or more of the neuroendocrine 
markers chromogranin, CD56, synaptophysin in more 
than 10% of the neoplastic cells.”17
In  the present  case ,  synaptophys in  and 
chromogranin A were expressed in more than 10% of 
the neoplastic cells. Pocrnich et al.5 have reported that 
the neuroendocrine marker most commonly expressed 
in neuroendocrine carcinoma of the endometrium is 
synaptophysin, and that expression of the three markers 
was seen in 5 of 25 cases (20%). In this case, there 
was diffuse expression of p16, which is also reported 
in other studies.4,5,7,18 The polypoid aspect is another 
characteristic present in several studies; however, it is 
not the only form of macroscopic presentation.7,17,18 
Multinucleated bizarre cells are not commonly observed 
in endometrial large cell neuroendocrine carcinomas; 
however, 16% of cases described by Pocrnich et al.5 
exhibited such a characteristic. Some studies report 
that endometrial small cell neuroendocrine carcinomas 
are more common than those of large cells, which 
makes this report even more unusual.6,18
In our patient’s case, there were unusual areas 
with melanocytic differentiation, which is rare in 
uterine neoplasms. There are few reports of this 
differentiation in carcinosarcoma.8,9 Neuroendocrine 
carcinomas are complex neoplasms composed of 
cells able to produce substances that can generate 
paraneoplastic syndromes, and melanin, through 
melanosomes present in these cells, which can be 
observed by electron microscopy.19
Endometrial neuroendocrine carcinoma is a rare, 
extremely aggressive neoplasia that requires a specific 
type of chemotherapy.5,14 In the literature, there was no 
report of the association between two rare conditions 
in endometrial neoplasms: large cell neuroendocrine 
carcinoma and melanocytic differentiation.
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